NCT00406497已完成2 期
Phase 2a Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- The variation from baseline in anterior chamber cell score on Day 14 (difference from baseline
研究概览
简要总结
The purpose of this phase 2 study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of postoperative inflammation.
详细描述
The objective is to assess efficacy endpoints in comparison with 0.1% BM ophthalmic solution, prior to investigation of the efficacy and safety of 0.05% DFBA ophthalmic emulsion in the treatment of postoperative intraocular inflammation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients undergoing intraocular surgery (cataract surgery, cataract surgery + implantation of intraocular lens, vitreous surgery, cataract surgery + implantation of intraocular lens + vitreous surgery)
- •Patients with anterior chamber cell score ≥2 on the next day of surgery
- •Male and female patients aged ≥20 years (on the day of obtaining informed consent)
- •Patients giving written informed consent prior to initiation of the study
排除标准
- •Patients who did not meet all of the above inclusion criteria
- •Patients receiving systemic administration of any corticosteroid or immunosuppressive drug, or topical application of corticosteroid ophthalmic ointment within 1 week before instillation of the investigational product
- •Patients receiving topical injection of any corticosteroid in eyes before instillation of the investigational product (aqueous preparation: within 1 week before instillation of the investigational product, depot preparation: within 2 weeks before instillation of the investigational product)
- •Patients receiving systemic administration of any non-steroidal anti-inflammatory drug or antiphlogistic enzyme
- •Patients receiving instillation of any corticosteroid, non-steroidal anti-inflammatory ophthalmic solution or antiphologistic enzyme within 24 hours before ophthalmic examination prior to instillation of the investigational product (on the next day of surgery) (except instillation of non-steroidal anti-inflammatory ophthalmic solution at 3, 2, 1 and 0.5 hours before surgery)
- •Patients with endogenous uveitis
- •Patients planning to undergo surgery of the contralateral eye during the study period
- •Patients with new intraocular bleeding after surgery
- •Patients receiving gas or silicon oil in the vitreous body
- •Patients with glaucoma or ocular hypertension (IOP on the next day of surgery ≥25 mmHg)
- •Patients with superficial punctuate keratopathy or corneal ulcer
- •Patients with any viral, bacterial or fungal keratoconjunctival disease
- •Patients with allergy to any corticosteroid
- •Patients requiring use of contact lens during the study period
- •Women who were or might be pregnant, or lactating women
- •Patients participating in another clinical study within 3 months before initiation of the present study
- •Patients undergoing surgery under systemic anesthesia
结局指标
主要结局
The variation from baseline in anterior chamber cell score on Day 14 (difference from baseline
score) was compared between the test and control groups.
次要结局
- The variations from baseline in anterior chamber cell score on Days 3 and 7 were compared
- between the test and control groups.
- The numbers of patients with an anterior chamber cell score of 0 on Days 7 and 14 were
- compared between the test and control groups.
- The variations from baseline in anterior chamber flare score on Days 3, 7 and 14 were
- The variations from baseline in total sign and symptom scores on Days 3, 7 and 14 were
研究者
相似试验
已完成
2 期
Study of Difluprednate Ophthalmic Emulsion in the Treatment of UveitisAnterior UveitisNCT00405496Sirion Therapeutics, Inc.24
已完成
2 期
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative InflammationInflammationNCT00407225Sirion Therapeutics, Inc.24
已完成
3 期
Study of Difluprednate Ophthalmic Emulsion in Postoperative InflammationInflammationNCT00406341Sirion Therapeutics, Inc.200
已完成
3 期
Study of Difluprednate Ophthalmic Emulsion in the Treatment of UveitisAnterior UveitisPanuveitisNCT00406887Sirion Therapeutics, Inc.140
已完成
3 期
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe UveitisPanuveitisUveitisNCT00407056Sirion Therapeutics, Inc.20